{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:43:34Z","timestamp":1790084614508,"version":"4.0.1"},"reference-count":17,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The availability of nonapproved psychoactive substances with addiction potential from internet sources poses a significant threat to public health. Polysubstance abuse or inadvertent contamination of preparations may result in clinically challenging intoxication and withdrawal syndromes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Report<\/jats:title>\n                  <jats:p>We report a case of a 32-year-old male with an approximate 2-year history of taking internet-obtained etizolam and tianeptine who presented to the hospital following an overdose. He experienced subsequent withdrawal symptoms consistent with benzodiazepine and opioid withdrawal. Initial attempts at managing symptoms with chlordiazepoxide 25 mg every 6 hours did not relieve his symptoms. On day 3 of admission, addiction medicine was consulted and his regimen was changed to diazepam 80 mg daily with additional as-needed diazepam based on etizolam equivalence. He also received a 5-day methadone taper with plans to transition to buprenorphine in the outpatient setting. Upon discharge he was referred to an addiction medicine specialist who was willing to continue a slow diazepam taper and initiate medications for opioid use disorder to manage both substance use disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This case report demonstrates the effectiveness of diazepam in managing benzodiazepine withdrawal from etizolam while concurrently using methadone to manage opioid withdrawal symptoms from tianeptine in a hospitalized patient following overdose. We highlight the importance of a warm handoff in considering the outpatient discharge plan.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2022.12.356","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:44:22Z","timestamp":1672847062000},"page":"356-359","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of concurrent etizolam and tianeptine withdrawal following accidental overdose"],"prefix":"10.9740","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-2213","authenticated-orcid":true,"given":"Marija","family":"Markovic","sequence":"first","affiliation":[{"name":"1 (Corresponding author) Clinical Pharmacy Specialist, Psychiatry, Hackensack University Medical Center, Hackensack, New Jersey, marija.markovic@hmhn.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0967-5023","authenticated-orcid":true,"given":"Dania","family":"Niwash","sequence":"additional","affiliation":[{"name":"2 Psychiatric Physician Assistant, Hackensack University Medical Center, Hackensack, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"2023010415433916000_i2168-9709-12-6-356-b01","unstructured":"Drug Enforcement Administration [Internet].\n          Drug and chemical evaluation section: etizolam [updated 2020 Mar; cited 2022 Sep 1]. Springfield (VA): US Department of Justice.\n          Available from: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/etizolam.pdf"},{"key":"2023010415433916000_i2168-9709-12-6-356-b02","unstructured":"WHO Expert Committee on Drug Dependence [Internet].\n          Critical review report: etizolam [updated 2019 Oct 21-25; cited 2021 Sep 22]. Geneva: World Health Organization; c2019.\n          Available from: https:\/\/www.who.int\/medicines\/access\/controlled-substances\/Final_Etizolam.pdf"},{"key":"2023010415433916000_i2168-9709-12-6-356-b03","doi-asserted-by":"crossref","unstructured":"Tamburin\n              S,\n            \n            \n              Mantovani\n              E,\n            \n            \n              Bertoldi\n              A,\n            \n            \n              Federico\n              A,\n            \n            \n              Casari\n              R,\n            \n            \n              Lugoboni\n              F.\n            \n          \n          High-dose dependence and cognitive side effects to medical prescription of etizolam.\n\t\t\t\t\tFront Psychiatry.\n\t\t\t\t\t2020;\n\t\t\t\t\t11:\n\t\t\t\t\t601827.\n\t\t\t\t\tDOI: 10.3389\/fpsyt.2020.601827. PubMed PMID: 33329156; PubMed Central PMCID: PMC7671959.","DOI":"10.3389\/fpsyt.2020.601827"},{"key":"2023010415433916000_i2168-9709-12-6-356-b04","doi-asserted-by":"crossref","unstructured":"Levine\n              M,\n            \n            \n              Lovecchio\n              F.\n            \n          \n          New designer drugs.\n\t\t\t\t\tEmerg Med Clin North Am.\n\t\t\t\t\t2021;\n\t\t\t\t\t39(3):\n\t\t\t\t\t677-\n\t\t\t\t\t87.\n\t\t\t\t\tDOI: 10.1016\/j.emc.2021.04.013. PubMed PMID: 34215409.","DOI":"10.1016\/j.emc.2021.04.013"},{"key":"2023010415433916000_i2168-9709-12-6-356-b05","doi-asserted-by":"crossref","unstructured":"El Balkhi\n              S,\n            \n            \n              Monchaud\n              C,\n            \n            \n              Herault\n              F,\n            \n            \n              G\u00e9niaux\n              H,\n            \n            \n              Saint-Marcoux\n              F.\n            \n          \n          Designer benzodiazepines' pharmacological effects and potencies: how to find the information.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2020;\n\t\t\t\t\t34(9):\n\t\t\t\t\t1021-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1177\/0269881119901096. PubMed PMID: 31971477.","DOI":"10.1177\/0269881119901096"},{"key":"2023010415433916000_i2168-9709-12-6-356-b06","doi-asserted-by":"crossref","unstructured":"Nielsen\n              S,\n            \n            \n              McAuley\n              A.\n            \n          \n          Etizolam: a rapid review on pharmacology, non-medical use and harms.\n\t\t\t\t\tDrug Alcohol Rev.\n\t\t\t\t\t2020;\n\t\t\t\t\t39(4):\n\t\t\t\t\t330-\n\t\t\t\t\t6.\n\t\t\t\t\tDOI: 10.1111\/dar.13052. PubMed PMID: 32243020.","DOI":"10.1111\/dar.13052"},{"key":"2023010415433916000_i2168-9709-12-6-356-b07","unstructured":"Drug Enforcement Administration [Internet].\n          Drug and chemical evaluation section: tianeptine [updated 2019 May; cited 2022 Sep 1]. Springfield (VA): US Department of Justice.\n          Available from: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/tianeptine.pdf"},{"key":"2023010415433916000_i2168-9709-12-6-356-b08","doi-asserted-by":"crossref","unstructured":"Rushton\n              W,\n            \n            \n              Whitworth\n              B,\n            \n            \n              Brown\n              J,\n            \n            \n              Kurz\n              M,\n            \n            \n              Rivera\n              J.\n            \n          \n          Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health.\n\t\t\t\t\tClin Toxicol.\n\t\t\t\t\t2021;\n\t\t\t\t\t59(2):\n\t\t\t\t\t152-\n\t\t\t\t\t7.\n\t\t\t\t\tDOI: 10.1080\/15563650.2020.1781151. PubMed PMID: 32552075.","DOI":"10.1080\/15563650.2020.1781151"},{"key":"2023010415433916000_i2168-9709-12-6-356-b09","doi-asserted-by":"crossref","unstructured":"Lauhan\n              R,\n            \n            \n              Hsu\n              A,\n            \n            \n              Alam\n              A,\n            \n            \n              Beizai\n              K.\n            \n          \n          Tianeptine abuse and dependence: case report and literature review.\n\t\t\t\t\tPsychosomatics.\n\t\t\t\t\t2018;\n\t\t\t\t\t59(6):\n\t\t\t\t\t547-\n\t\t\t\t\t53.\n\t\t\t\t\tDOI: 10.1016\/j.psym.2018.07.006. PubMed PMID: 30149933.","DOI":"10.1016\/j.psym.2018.07.006"},{"key":"2023010415433916000_i2168-9709-12-6-356-b10","unstructured":"Hardman\n              MI,\n            \n            \n              Sprung\n              J,\n            \n            \n              Weingarten\n              TN.\n            \n          \n          Acute phenibut withdrawal: a comprehensive literature review and illustrative case report.\n\t\t\t\t\tBosn J Basic Med Sci.\n\t\t\t\t\t2019;\n\t\t\t\t\t19(2):\n\t\t\t\t\t125-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.17305\/bjbms.2018.4008. PubMed PMID: 30501608; PubMed Central PMCID: PMC6535394."},{"key":"2023010415433916000_i2168-9709-12-6-356-b11","doi-asserted-by":"crossref","unstructured":"Altamura\n              AC,\n            \n            \n              Moliterno\n              D,\n            \n            \n              Paletta\n              S,\n            \n            \n              Maffini\n              M,\n            \n            \n              Mauri\n              MC,\n            \n            \n              Bareggi\n              S.\n            \n          \n          Understanding the pharmacokinetics of anxiolytic drugs.\n\t\t\t\t\tExpert Opin Drug Metab Toxicol.\n\t\t\t\t\t2013;\n\t\t\t\t\t9(4):\n\t\t\t\t\t423-\n\t\t\t\t\t40.\n\t\t\t\t\tDOI: 10.1517\/17425255.2013.759209. PubMed PMID: 23330992.","DOI":"10.1517\/17425255.2013.759209"},{"key":"2023010415433916000_i2168-9709-12-6-356-b12","doi-asserted-by":"crossref","unstructured":"Carpenter\n              JE,\n            \n            \n              Murray\n              BP,\n            \n            \n              Dunkley\n              C,\n            \n            \n              Kazzi\n              ZN,\n            \n            \n              Gittinger\n              MH.\n            \n          \n          Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014\u20132017.\n\t\t\t\t\tClin Toxicol.\n\t\t\t\t\t2019;\n\t\t\t\t\t57(4):\n\t\t\t\t\t282-\n\t\t\t\t\t6.\n\t\t\t\t\tDOI: 10.1080\/15563650.2018.1510502. PubMed PMID: 30430874.","DOI":"10.1080\/15563650.2018.1510502"},{"key":"2023010415433916000_i2168-9709-12-6-356-b13","doi-asserted-by":"crossref","unstructured":"Garland\n              JM,\n            \n            \n              Hull\n              JD,\n            \n            \n              Bender\n              CL,\n            \n            \n              Marshall\n              L,\n            \n            \n              Holt\n              AC.\n            \n          \n          Evidence of designer benzodiazepine use in routine healthcare urine drug specimens.\n\t\t\t\t\tJ Addict Med.\n\t\t\t\t\t2022;\n\t\t\t\t\t16(3):\n\t\t\t\t\t354-\n\t\t\t\t\t6.\n\t\t\t\t\tDOI: 10.1097\/ADM.0000000000000884. PubMed PMID: 34172626.","DOI":"10.1097\/ADM.0000000000000884"},{"key":"2023010415433916000_i2168-9709-12-6-356-b14","doi-asserted-by":"crossref","unstructured":"El Zahran\n              T,\n            \n            \n              Schier\n              J,\n            \n            \n              Glidden\n              E,\n            \n            \n              Kieszak\n              S,\n            \n            \n              Law\n              R,\n            \n            \n              Bottei\n              E,\n            \n            et al.\n          \n          Characteristics of tianeptine exposures reported to the National Poison Data System \u2014 United States, 2000\u20132017.\n\t\t\t\t\tMMWR Morb Mortal Wkly Rep.\n\t\t\t\t\t2018;\n\t\t\t\t\t67(30):\n\t\t\t\t\t815-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.15585\/mmwr.mm6730a2. PubMed PMID: 30070980; PubMed Central PMCID: PMC6072055.","DOI":"10.15585\/mmwr.mm6730a2"},{"key":"2023010415433916000_i2168-9709-12-6-356-b15","doi-asserted-by":"crossref","unstructured":"Trowbridge\n              P,\n            \n            \n              Walley\n              AY.\n            \n          \n          Use of buprenorphine-naloxone in the treatment of tianeptine use disorder.\n\t\t\t\t\tJ Addict Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t13(4):\n\t\t\t\t\t331-\n\t\t\t\t\t3.\n\t\t\t\t\tDOI: 10.1097\/ADM.0000000000000490. PubMed PMID: 30550394.","DOI":"10.1097\/ADM.0000000000000490"},{"key":"2023010415433916000_i2168-9709-12-6-356-b16","doi-asserted-by":"crossref","unstructured":"Szczesniak\n              L,\n            \n            \n              Sullivan\n              R.\n            \n          \n          Microdose induction of buprenorphine in a patient using tianeptine.\n\t\t\t\t\tJ Addict Med.\n\t\t\t\t\t2022;\n\t\t\t\t\t16(6):\n\t\t\t\t\t736-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1097\/ADM.0000000000001003. PubMed PMID: 35709488.","DOI":"10.1097\/ADM.0000000000001003"},{"key":"2023010415433916000_i2168-9709-12-6-356-b17","doi-asserted-by":"crossref","unstructured":"Inada\n              T,\n            \n            \n              Inagaki\n              A.\n            \n          \n          Psychotropic dose equivalence in Japan.\n\t\t\t\t\tPsychiatry Clin Neurosci.\n\t\t\t\t\t2015;\n\t\t\t\t\t69(8):\n\t\t\t\t\t440-\n\t\t\t\t\t7.\n\t\t\t\t\tDOI: 10.1111\/pcn.12275. PubMed PMID: 25601291.","DOI":"10.1111\/pcn.12275"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/6\/356\/3175409\/i2168-9709-12-6-356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/6\/356\/3175409\/i2168-9709-12-6-356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:35Z","timestamp":1731687815000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/12\/6\/article-p356.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,1,5]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2022.12.356","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}